Literature DB >> 8781700

Expression of the CD44 variant isoforms 6 and 4/5 in breast cancer. Correlation with established prognostic parameters.

P A Regidor1, R Callies, M Regidor, U Günthert, M Zöller, A E Schindler.   

Abstract

Eighty one invasive breast cancers were analysed immunohistochemically to detect if they expressed the adhesion molecules CD44 v6 and v4/5, and the results were evaluated using the semiquantitative IR-score. The results were further divided into four groups: negative, weak positive, moderate positive and strong positive. Fifteen benign breast tumors were also analysed. Sixty eight breast cancers were CD44v6 and v4/5 positive. T3 and T4 cancers showed statistically significant higher positive CD44 rates than T1 and T2 cancers (P < 0.05). We also found a statistically significant correlation between the estrogen receptor and the CD44 status and between the CD44 status and the cathepsin-D status, whereas no correlation between CD44 and the lymph node status, the M status, the grading of the tumors, the progesterone receptor and the menopausal status could be found. Eleven benign tumors were CD44v6 and v4/5 positive. We could not establish any correlation between the expression of CD44 and the metastasizing capacity of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8781700     DOI: 10.1007/s004040050113

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  32 in total

1.  A new cell adhesion mechanism involving hyaluronate and CD44.

Authors:  K Miyake; P W Kincade
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

Review 2.  Breast cancer (1)

Authors:  J R Harris; M E Lippman; U Veronesi; W Willett
Journal:  N Engl J Med       Date:  1992-07-30       Impact factor: 91.245

3.  Isolation and DNA sequence of a cDNA clone encoding a lymphocyte adhesion receptor for high endothelium.

Authors:  R L Idzerda; W G Carter; C Nottenburg; E A Wayner; W M Gallatin; T St John
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

4.  Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma.

Authors:  S Jalkanen; H Joensuu; K O Söderström; P Klemi
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

Review 5.  Are CD44 variant isoforms involved in human tumour progression?

Authors:  U Günthert; R Stauder; B Mayer; H J Terpe; L Finke; K Friedrichs
Journal:  Cancer Surv       Date:  1995

Review 6.  Functional role of CD44 (Pgp-1) on activated B cells.

Authors:  S Murakami; K Miyake; P W Kincade; R J Hodes
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

7.  CD44 variant exon epitopes in primary breast cancer and length of survival.

Authors:  M Kaufmann; K H Heider; H P Sinn; G von Minckwitz; H Ponta; P Herrlich
Journal:  Lancet       Date:  1995-03-11       Impact factor: 79.321

8.  Mouse T lymphoma cells contain a transmembrane glycoprotein (GP85) that binds ankyrin.

Authors:  E L Kalomiris; L Y Bourguignon
Journal:  J Cell Biol       Date:  1988-02       Impact factor: 10.539

9.  Identification of multiple cell adhesion receptors for collagen and fibronectin in human fibrosarcoma cells possessing unique alpha and common beta subunits.

Authors:  E A Wayner; W G Carter
Journal:  J Cell Biol       Date:  1987-10       Impact factor: 10.539

10.  A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps.

Authors:  K H Heider; M Hofmann; E Hors; F van den Berg; H Ponta; P Herrlich; S T Pals
Journal:  J Cell Biol       Date:  1993-01       Impact factor: 10.539

View more
  4 in total

Review 1.  Hyaluronan-CD44 interactions as potential targets for cancer therapy.

Authors:  Suniti Misra; Paraskevi Heldin; Vincent C Hascall; Nikos K Karamanos; Spyros S Skandalis; Roger R Markwald; Shibnath Ghatak
Journal:  FEBS J       Date:  2011-03-25       Impact factor: 5.542

2.  CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast.

Authors:  G M K Tse; P-H Tan; T K F Ma; C B Gilks; C S P Poon; B K B Law
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

Review 3.  CD44 in inflammation and metastasis.

Authors:  J Lesley; R Hyman; N English; J B Catterall; G A Turner
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

4.  CD44s as a surrogate marker for distinguishing intraductal papilloma from papillary carcinoma of the breast.

Authors:  M Saddik; R Lai
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.